JPMorgan Chase & Co. Boosts Stryker (NYSE:SYK) Price Target to $445.00

Stryker (NYSE:SYK) had its target price hoisted by JPMorgan Chase & Co. from $420.00 to $445.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the medical technology company’s stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 13.96% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Citigroup increased their target price on shares of Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Stifel Nicolaus raised their price objective on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday. UBS Group raised their price objective on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Robert W. Baird raised their price objective on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Finally, Wells Fargo & Company raised their price objective on shares of Stryker from $405.00 to $427.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $416.40.

Stryker Trading Down 0.2 %

Shares of SYK stock opened at $390.48 on Wednesday. Stryker has a 52-week low of $314.93 and a 52-week high of $406.19. The stock has a market cap of $148.86 billion, a price-to-earnings ratio of 41.85, a P/E/G ratio of 2.68 and a beta of 0.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The firm has a fifty day moving average of $376.55 and a 200-day moving average of $362.18.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 16.34% and a return on equity of 23.07%. During the same period in the previous year, the business posted $3.46 earnings per share. On average, equities research analysts forecast that Stryker will post 12.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 5.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Blue Zone Wealth Advisors LLC lifted its stake in Stryker by 1.2% in the fourth quarter. Blue Zone Wealth Advisors LLC now owns 20,912 shares of the medical technology company’s stock valued at $7,529,000 after buying an additional 243 shares in the last quarter. WD Rutherford LLC lifted its stake in Stryker by 1.6% in the fourth quarter. WD Rutherford LLC now owns 10,630 shares of the medical technology company’s stock valued at $3,827,000 after buying an additional 163 shares in the last quarter. Strategic Financial Concepts LLC bought a new position in Stryker in the fourth quarter valued at approximately $55,769,000. Principal Securities Inc. lifted its stake in Stryker by 21.5% in the fourth quarter. Principal Securities Inc. now owns 7,584 shares of the medical technology company’s stock valued at $2,731,000 after buying an additional 1,340 shares in the last quarter. Finally, Everhart Financial Group Inc. lifted its stake in Stryker by 2.4% in the fourth quarter. Everhart Financial Group Inc. now owns 3,245 shares of the medical technology company’s stock valued at $1,168,000 after buying an additional 75 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.